Trial · NCT02590068
Effects of Chronic Viral Infection on Immune Response to Zoster Vaccination
NCT02590068, Not applicable, Terminated, Rockefeller University; results first posted 2019-12-18
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Effects of Chronic Viral Infection on Immune Response to Zoster Vaccination. Trials, record NCT02590068. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT02590068
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Effects of Chronic Viral Infection on Immune Response to Zoster Vaccination
- NCT number
- NCT02590068
- Status
- Terminated
- Phases
- Not applicable
- Enrollment
- 14 participants, actual
- Lead sponsor
- Rockefeller University
- Conditions
- Hepatitis C
- Interventions
- Zoster vaccine live
- First posted
- 2015-10-28
- Last updated
- 2019-12-18
- Results first posted
- 2019-12-18
Source ClinicalTrials.gov
Registered outcomes5
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Serum Zoster Antibody Level | 18 months | Serum zoster antibody level would be measured by gpELISA expressed in (units/mL) |
| Secondary | Interferon Stimulated Gene (ISG) Expression | 18 months | Interferon stimulated gene (ISG) expression in PBMC will be expressed as fold-change (FCH) above baseline |
| Secondary | Serum Biomarkers of Immune Activation(Expressed in%) | 18 months | Serum biomarkers of immune activation will be measured and expressed in percentage. |
| Secondary | Responder Cell Frequency | 18 months | Responder cell frequency: VZV specific CD4+ T cells post-vaccination (expressed in %) |
| Secondary | Interferon-gamma Response | 18 months | Interferon-gamma response: by ELIspot expressed as number of spot-forming cells per million PBMCs |
Source ClinicalTrials.gov
Outcomes5
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Serum Zoster Antibody Level | 18 months | Samples were collected but none were tested for antibody levels | ||
| SECONDARY | Interferon Stimulated Gene (ISG) Expression | 18 months | Samples were collected and cryopreserved. RNA was collected for these samples and batched, but the RNA-Seq (for RNA expression measurements) was not run. The samples wee not analyzed and no assays were performed for this protocol. | ||
| SECONDARY | Serum Biomarkers of Immune Activation(Expressed in%) | 18 months | Samples were not analyzed and no assays were performed for this protocol. | ||
| SECONDARY | Responder Cell Frequency | 18 months | Samples were not analyzed and no assays were performed for this protocol. | ||
| SECONDARY | Interferon-gamma Response | 18 months | Samples were not analyzed and no assays were performed for this protocol. |
Source ClinicalTrials.gov
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow6
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Overall Study | STARTED | Hepatitis C Infected Volunteers | 0 | |
| Overall Study | STARTED | Healthy Volunteers | 14 | |
| Overall Study | COMPLETED | Hepatitis C Infected Volunteers | 0 | |
| Overall Study | COMPLETED | Healthy Volunteers | 14 | |
| Overall Study | NOT COMPLETED | Hepatitis C Infected Volunteers | 0 | |
| Overall Study | NOT COMPLETED | Healthy Volunteers | 0 |
Source ClinicalTrials.gov
Adverse events14
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| other | Mild Anemia | Blood and lymphatic system disorders | Hepatitis C Infected Volunteers | 0 | 0 | 0 |
| other | Mild Anemia | Blood and lymphatic system disorders | Healthy Volunteers | 1 | 14 | 1 |
| other | Mild Back Pain | Musculoskeletal and connective tissue disorders | Hepatitis C Infected Volunteers | 0 | 0 | 0 |
| other | Mild Back Pain | Musculoskeletal and connective tissue disorders | Healthy Volunteers | 1 | 14 | 1 |
| other | Dental Filling Fell Out | Gastrointestinal disorders | Hepatitis C Infected Volunteers | 0 | 0 | 0 |
| other | Dental Filling Fell Out | Gastrointestinal disorders | Healthy Volunteers | 1 | 14 | 1 |
| other | Anxiety | Psychiatric disorders | Hepatitis C Infected Volunteers | 0 | 0 | 0 |
| other | Anxiety | Psychiatric disorders | Healthy Volunteers | 1 | 14 | 1 |
| other | Lightheadedness | General disorders | Hepatitis C Infected Volunteers | 0 | 0 | 0 |
| other | Lightheadedness | General disorders | Healthy Volunteers | 1 | 14 | 1 |
1 to 10 of 14Source ClinicalTrials.gov
See all 14 adverse eventsAdverse event totals6
The totals the trial posted for each group.
| Total | Group | Affected | At risk |
|---|---|---|---|
| Total, all-cause mortality | Hepatitis C Infected Volunteers | 0 | 0 |
| Total, all-cause mortality | Healthy Volunteers | 0 | 14 |
| Total, other adverse events | Hepatitis C Infected Volunteers | 0 | 0 |
| Total, other adverse events | Healthy Volunteers | 4 | 14 |
| Total, serious adverse events | Hepatitis C Infected Volunteers | 0 | 0 |
| Total, serious adverse events | Healthy Volunteers | 1 | 14 |
Source ClinicalTrials.gov
Papers22
The papers the trial lists on ClinicalTrials.gov.
Grants1
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
| Project | Title | Principal investigators | Organization | Funder | Fiscal years |
|---|---|---|---|---|---|
| U19AI111825 | Integrating innate and adaptive pathways in vaccine responses | RAVETCH, JEFFREY VICTOR | ROCKEFELLER UNIVERSITY | NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES | 2014 to 2023 |
Source NIH RePORTER
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT02590068
GET https://conductscience.org/api/trials/v1/NCT02590068/papers?page=2